| Product Code: ETC13325944 | Publication Date: Apr 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 150 | No. of Figures: 55 | No. of Tables: 32 |
North America Immunotherapy Drugs Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 North America Immunotherapy Drugs Market Overview |
3.1 North America Regional Macro Economic Indicators |
3.2 North America Immunotherapy Drugs Market Revenues & Volume, 2021 & 2031F |
3.3 North America Immunotherapy Drugs Market - Industry Life Cycle |
3.4 North America Immunotherapy Drugs Market - Porter's Five Forces |
3.5 North America Immunotherapy Drugs Market Revenues & Volume Share, By Countries, 2021 & 2031F |
3.6 North America Immunotherapy Drugs Market Revenues & Volume Share, By Drug Type, 2021 & 2031F |
3.7 North America Immunotherapy Drugs Market Revenues & Volume Share, By Cancer Type, 2021 & 2031F |
3.8 North America Immunotherapy Drugs Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.9 North America Immunotherapy Drugs Market Revenues & Volume Share, By Mechanism of Action, 2021 & 2031F |
3.10 North America Immunotherapy Drugs Market Revenues & Volume Share, By Sales Channel, 2021 & 2031F |
4 North America Immunotherapy Drugs Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 North America Immunotherapy Drugs Market Trends |
6 North America Immunotherapy Drugs Market, 2021 - 2031 |
6.1 North America Immunotherapy Drugs Market, Revenues & Volume, By Drug Type, 2021 - 2031 |
6.1.1 Overview & Analysis |
6.1.2 North America Immunotherapy Drugs Market, Revenues & Volume, By Checkpoint Inhibitors, 2021 - 2031 |
6.1.3 North America Immunotherapy Drugs Market, Revenues & Volume, By Monoclonal Antibodies, 2021 - 2031 |
6.1.4 North America Immunotherapy Drugs Market, Revenues & Volume, By Cancer Vaccines, 2021 - 2031 |
6.1.5 North America Immunotherapy Drugs Market, Revenues & Volume, By Cytokines, 2020 - 2028 |
6.1.6 North America Immunotherapy Drugs Market, Revenues & Volume, By Adoptive T-Cell Therapy, 2020 - 2028 |
6.2 North America Immunotherapy Drugs Market, Revenues & Volume, By Cancer Type, 2021 - 2031 |
6.2.1 Overview & Analysis |
6.2.2 North America Immunotherapy Drugs Market, Revenues & Volume, By Lung Cancer, 2021 - 2031 |
6.2.3 North America Immunotherapy Drugs Market, Revenues & Volume, By Breast Cancer, 2021 - 2031 |
6.2.4 North America Immunotherapy Drugs Market, Revenues & Volume, By Melanoma, 2021 - 2031 |
6.2.5 North America Immunotherapy Drugs Market, Revenues & Volume, By Leukemia, 2021 - 2031 |
6.2.6 North America Immunotherapy Drugs Market, Revenues & Volume, By Multiple Myeloma, 2020 - 2028 |
6.3 North America Immunotherapy Drugs Market, Revenues & Volume, By End User, 2021 - 2031 |
6.3.1 Overview & Analysis |
6.3.2 North America Immunotherapy Drugs Market, Revenues & Volume, By Oncology Centers, 2021 - 2031 |
6.3.3 North America Immunotherapy Drugs Market, Revenues & Volume, By Hospitals, 2021 - 2031 |
6.3.4 North America Immunotherapy Drugs Market, Revenues & Volume, By Specialty Clinics, 2021 - 2031 |
6.3.5 North America Immunotherapy Drugs Market, Revenues & Volume, By Research Institutions, 2021 - 2031 |
6.3.6 North America Immunotherapy Drugs Market, Revenues & Volume, By Pharmaceutical Companies, 2021 - 2031 |
6.4 North America Immunotherapy Drugs Market, Revenues & Volume, By Mechanism of Action, 2021 - 2031 |
6.4.2 North America Immunotherapy Drugs Market, Revenues & Volume, By PD-1/PD-L1 Blocking, 2021 - 2031 |
6.4.3 North America Immunotherapy Drugs Market, Revenues & Volume, By Immune System Activation, 2021 - 2031 |
6.4.4 North America Immunotherapy Drugs Market, Revenues & Volume, By Tumor Cell Recognition, 2020 - 2028 |
6.4.5 North America Immunotherapy Drugs Market, Revenues & Volume, By Signal Pathway Modulation, 2020 - 2028 |
6.4.6 North America Immunotherapy Drugs Market, Revenues & Volume, By CAR-T Cell Therapy, 2020 - 2028 |
6.5 North America Immunotherapy Drugs Market, Revenues & Volume, By Sales Channel, 2020 - 2028 |
6.5.1 Overview & Analysis |
6.5.2 North America Immunotherapy Drugs Market, Revenues & Volume, By Direct Sales, 2020 - 2028 |
6.5.3 North America Immunotherapy Drugs Market, Revenues & Volume, By Online Pharmacies, 2020 - 2028 |
6.5.4 North America Immunotherapy Drugs Market, Revenues & Volume, By Wholesale Suppliers, 2020 - 2028 |
6.5.5 North America Immunotherapy Drugs Market, Revenues & Volume, By Government Procurement, 2020 - 2028 |
6.5.6 North America Immunotherapy Drugs Market, Revenues & Volume, By Hospital Contracts, 2020 - 2028 |
7 North America Immunotherapy Drugs Market, By Countries, 2021 - 2031 |
7.1 Overview & Analysis |
7.2 North America Immunotherapy Drugs Market, Revenues & Volume, By Drug Type, 2021 - 2031 |
7.2.1 United States (US) Immunotherapy Drugs Market, Revenues & Volume, By Drug Type, 2021 - 2031 |
7.2.2 Canada Immunotherapy Drugs Market, Revenues & Volume, By Drug Type, 2021 - 2031 |
7.2.3 Rest of North America Immunotherapy Drugs Market, Revenues & Volume, By Drug Type, 2021 - 2031 |
7.3 North America Immunotherapy Drugs Market Revenues & Volume Share, By Cancer Type, 2021 & 2031F |
7.3.1 United States (US) Immunotherapy Drugs Market, Revenues & Volume, By Cancer Type, 2021 - 2031 |
7.3.2 Canada Immunotherapy Drugs Market, Revenues & Volume, By Cancer Type, 2021 - 2031 |
7.3.3 Rest of North America Immunotherapy Drugs Market, Revenues & Volume, By Cancer Type, 2021 - 2031 |
7.4 North America Immunotherapy Drugs Market, Revenues & Volume, By End User, 2021 - 2031 |
7.4.1 United States (US) Immunotherapy Drugs Market, Revenues & Volume, By End User, 2021 - 2031 |
7.4.2 Canada Immunotherapy Drugs Market, Revenues & Volume, By End User, 2021 - 2031 |
7.4.3 Rest of North America Immunotherapy Drugs Market, Revenues & Volume, By End User, 2021 - 2031 |
7.5 North America Immunotherapy Drugs Market, Revenues & Volume, By Mechanism of Action, 2021 - 2031 |
7.5.1 United States (US) Immunotherapy Drugs Market, Revenues & Volume, By Mechanism of Action, 2021 - 2031 |
7.5.2 Canada Immunotherapy Drugs Market, Revenues & Volume, By Mechanism of Action, 2021 - 2031 |
7.5.3 Rest of North America Immunotherapy Drugs Market, Revenues & Volume, By Mechanism of Action, 2021 - 2031 |
7.6 North America Immunotherapy Drugs Market, Revenues & Volume, By Sales Channel, 2021 - 2031 |
7.6.1 United States (US) Immunotherapy Drugs Market, Revenues & Volume, By Sales Channel, 2021 - 2031 |
7.6.2 Canada Immunotherapy Drugs Market, Revenues & Volume, By Sales Channel, 2021 - 2031 |
7.6.3 Rest of North America Immunotherapy Drugs Market, Revenues & Volume, By Sales Channel, 2021 - 2031 |
8 North America Immunotherapy Drugs Market Key Performance Indicators |
9 North America Immunotherapy Drugs Market - Export/Import By Countries Assessment |
10 North America Immunotherapy Drugs Market - Opportunity Assessment |
10.1 North America Immunotherapy Drugs Market Opportunity Assessment, By Countries, 2021 & 2031F |
10.2 North America Immunotherapy Drugs Market Opportunity Assessment, By Drug Type, 2021 & 2031F |
10.3 North America Immunotherapy Drugs Market Opportunity Assessment, By Cancer Type, 2021 & 2031F |
10.4 North America Immunotherapy Drugs Market Opportunity Assessment, By End User, 2021 & 2031F |
10.5 North America Immunotherapy Drugs Market Opportunity Assessment, By Mechanism of Action, 2021 & 2031F |
10.6 North America Immunotherapy Drugs Market Opportunity Assessment, By Sales Channel, 2021 & 2031F |
11 North America Immunotherapy Drugs Market - Competitive Landscape |
11.1 North America Immunotherapy Drugs Market Revenue Share, By Companies, 2022 |
11.2 North America Immunotherapy Drugs Market Competitive Benchmarking, By Operating and Technical Parameters |
12 Top 10 Company Profiles |
13 Recommendations |
14 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here